Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009, Article ID 438673, 10 pages
http://dx.doi.org/10.1155/2009/438673
Research Article

A Dominant-Negative PPAR Mutant Promotes Cell Cycle Progression and Cell Growth in Vascular Smooth Muscle Cells

1The Methodist Hospital Research Institute, Houston, TX 77030, USA
2Takeda America Holdings, Deerfield, IL 60015, USA

Received 3 September 2009; Accepted 24 November 2009

Academic Editor: Tianxin Yang

Copyright © 2009 Joey Z. Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ross, “Cell biology of atherosclerosis,” Annual Review of Physiology, vol. 57, pp. 791–804, 1995. View at Google Scholar · View at Scopus
  2. P. P. Roux and J. Blenis, “ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions,” Microbiology and Molecular Biology Reviews, vol. 68, no. 2, pp. 320–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-C. Chambard, R. Lefloch, J. Pouyssegur, and P. Lenormand, “ERK implication in cell cycle regulation,” Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1299–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. W. Hiebert, S. P. Chellappan, J. M. Horowitz, and J. R. Nevins, “The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F,” Genes and Development, vol. 6, no. 2, pp. 177–185, 1992. View at Google Scholar · View at Scopus
  5. B. K. Tye, “MCM proteins in DNA replication,” Annual Review of Biochemistry, vol. 68, pp. 649–686, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Wakino, U. Kintscher, S. Kim, F. Yin, W. A. Hsueh, and R. E. Law, “Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1S transition in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 275, no. 29, pp. 22435–22441, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. R. E. Law, W. P. Meehan, X.-P. Xi et al., “Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia,” Journal of Clinical Investigation, vol. 98, no. 8, pp. 1897–1905, 1996. View at Google Scholar · View at Scopus
  8. K. Graf, X.-P. Xi, W. A. Hsueh, and R. E. Law, “Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells,” FEBS Letters, vol. 400, no. 1, pp. 119–121, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. S. T. de Dios, D. Bruemmer, R. J. Dilley et al., “Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-? ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation,” Circulation, vol. 107, no. 20, pp. 2548–2550, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Bruemmer, J. P. Berger, J. Liu et al., “A non-thiazolidinedione partial peroxisome proliferator-activated receptor ? ligand inhibits vascular smooth muscle cell growth,” European Journal of Pharmacology, vol. 466, no. 3, pp. 225–234, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. C. J. Hupfeld and R. H. Weiss, “TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27,” American Journal of Physiology, vol. 281, no. 2, pp. E207–E216, 2001. View at Google Scholar · View at Scopus
  12. D. B. Savage, G. D. Tan, C. L. Acerini et al., “Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-?,” Diabetes, vol. 52, no. 4, pp. 910–917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Gurnell, D. B. Savage, V. K. K. Chatterjee, and S. O'Rahilly, “The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2412–2421, 2003. View at Google Scholar · View at Scopus
  14. C. M. Halabi, A. M. Beyer, W. J. de Lange et al., “Interference with PPAR? function in smooth muscle causes vascular dysfunction and hypertension,” Cell Metabolism, vol. 7, no. 3, pp. 215–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. K. Semple, A. Meirhaeghe, A. J. Vidal-Puig et al., “A dominant negative human peroxisome proliferator-activated receptor (PPAR)a is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms,” Endocrinology, vol. 146, no. 4, pp. 1871–1882, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Gurnell, J. M. Wentworth, M. Agostini et al., “A dominant-negative peroxisome proliferator-activated receptor ? (PPAR?) mutant is a constitutive repressor and inhibits PPAR?-mediated adipogenesis,” The Journal of Biological Chemistry, vol. 275, no. 8, pp. 5754–5759, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Lim, C. J. Jin, M. Kim et al., “PPAR? gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 4, pp. 808–813, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Meredith, M. Panchatcharam, S. Miriyala et al., “Dominant-negative loss of PPAR? function enhances smooth muscle cell proliferation, migration, and vascular remodeling,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 465–471, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Elbrecht, Y. Chen, C. A. Cullinan et al., “Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors ?1 and ?2,” Biochemical and Biophysical Research Communications, vol. 224, no. 2, pp. 431–437, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Wang, L. Verna, N.-G. Chen et al., “Constitutive activation of peroxisome proliferator-activated receptor-? suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 34176–34181, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Bruemmer, F. Yin, J. Liu et al., “Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells,” Circulation Research, vol. 93, no. 4, pp. e38–e47, 2003. View at Google Scholar · View at Scopus
  23. P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994. View at Google Scholar · View at Scopus
  24. T. Force and J. V. Bonventre, “Growth factors and mitogen-activated protein kinases,” Hypertension, vol. 31, no. 1, part 1, pp. 152–161, 1998. View at Google Scholar
  25. D. Bruemmer, A. R. Collins, G. Noh et al., “Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice,” Journal of Clinical Investigation, vol. 112, no. 9, pp. 1318–1331, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Wang, G. Yang, Z. Jia et al., “Vascular PPAR? controls circadian variation in blood pressure and heart rate through Bmal1,” Cell Metabolism, vol. 8, no. 6, pp. 482–491, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Chang, L. Villacorta, J. Zhang et al., “Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-? deletion leads to hypotension,” Circulation, vol. 119, no. 16, pp. 2161–2169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. J. Sherr and J. M. Roberts, “CDK inhibitors: positive and negative regulators of G1-phase progression,” Genes and Development, vol. 13, no. 12, pp. 1501–1512, 1999. View at Google Scholar · View at Scopus
  29. M. Cheng, P. Olivier, J. A. Diehl et al., “The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts,” EMBO Journal, vol. 18, no. 6, pp. 1571–1583, 1999. View at Google Scholar · View at Scopus
  30. A. Sgambato, Y.-J. Zhang, N. Arber et al., “Deregulated expression of p27(Kip1) in human breast cancers,” Clinical Cancer Research, vol. 3, no. 10, pp. 1879–1887, 1997. View at Google Scholar · View at Scopus
  31. S. Fredersdorf, J. Burns, A. M. Milne et al., “High level expression of p27(Kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 12, pp. 6380–6385, 1997. View at Google Scholar · View at Scopus
  32. G. Pages, P. Lenormand, G. L'Allemain, J.-C. Chambard, S. Meloche, and J. Pouyssegur, “Mitogen-activated protein kinases p42(mapk) and p44(mapk) are required for fibroblast proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 18, pp. 8319–8323, 1993. View at Google Scholar · View at Scopus
  33. J. N. Lavoie, G. L'Allemain, A. Brunei, R. Müller, and J. Pouysségur, “Cyclin D1 expression is regulated positively by the p42/p44(MAPK) and negatively by the p38/HOG(MAPK) pathway,” The Journal of Biological Chemistry, vol. 271, no. 34, pp. 20608–20616, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Bruemmer, F. Yin, J. Liu et al., “Expression of minichromosome maintenance proteins in vascular smooth muscle cells is ERK/MAPK dependent,” Experimental Cell Research, vol. 290, no. 1, pp. 28–37, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Goetze, U. Kintscher, S. Kim et al., “Peroxisome proliferator-activated receptor-? ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration,” Journal of Cardiovascular Pharmacology, vol. 38, no. 6, pp. 909–921, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. I. B. Leibiger, B. Leibiger, and P.-O. Berggren, “Insulin signaling in the pancreatic β-cell,” Annual Review of Nutrition, vol. 28, pp. 233–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Ahuja, P. Sdek, and W. R. MacLellan, “Cardiac myocyte cell cycle control in development, disease, and regeneration,” Physiological Reviews, vol. 87, no. 2, pp. 521–544, 2007. View at Publisher · View at Google Scholar · View at Scopus